Aurobindo Pharma Launches Pomalidomide Capsules in $3.3B US Market

Aurobindo Pharma has taken a big step into the US oncology market with its wholly owned subsidiary, Eugia Pharma Specialities Limited, launching Pomalidomide Capsules in the United States.

The product marks a key expansion of Aurobindo’s specialty drug portfolio in what is one of the world’s most competitive and highest value generics markets.

The capsules, now available in 1 mg, 2 mg, 3 mg, and 4 mg, are the generic equivalent of Pomalyst — a leading immunomodulatory drug used to treat serious blood disorders and cancers. Eugia Pharma was among the first companies to file an ANDA (Abbreviated New Drug Application) for this product, giving it an early mover edge.

“Yes, we’ll be launching and we have already prepared for the launch.”— Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited, on Aurobindo’s involvement in the generic Pomalidomide (Pomalyst) launch in the U.S. market.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

Pomalidomide plays a vital role in modern oncology. It’s used with dexamethasone and sometimes bortezomib to treat relapsed or refractory multiple myeloma, and it’s also approved for AIDS related Kaposi sarcoma. Doctors increasingly rely on such generics to give patients access to proven therapies at lower costs than branded options.

The move comes as demand for affordable, complex generics keeps growing in the U.S. market. With this launch, Aurobindo not only broadens its oncology range but also positions itself to compete more effectively with other players in high growth therapeutic areas.

Investors have taken note of the development. While the stock dipped slightly on the Bombay Stock Exchange following the announcement, analysts see the strategy as a long-term boost to earnings and a way to diversify revenues beyond core generics.

“We are pleased to launch Pomalidomide Capsules in the U.S. This further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to making specialty medicines accessible to patients worldwide. We look forward to bringing more complex and specialty products to the market in the coming years,” said Rajeev Nannapaneni, Vice Chairman and CEO, NATCO Pharma Limited on Natco Pharma’s own Pomalidomide launch.

Key Data, Market Stats & Company Highlights

Market & Product Stats

• Estimated U.S. Pomalidomide market size: ~US$ 3.3 billion annually (IQVIA MAT data for the 12 months ending January?2026).
• Available strengths: 1mg, 2mg, 3mg, 4mg.
• Therapeutic uses: Treatment of relapsed/refractory multiple myeloma; AIDS?related Kaposi sarcoma.
• Manufacturing site: Eugia Pharma Unit I facility.

Company Metrics & Strategy

• First-to-File ANDA status gives potential early entry advantage in U.S. generics space.
• Aurobindo Pharma Q3 FY26 performance: Net profit up ~7.6% and net sales up ~9% year-on-year, reflecting ongoing operational growth.
• Global reach: Aurobindo operates in over 150 countries with more than 30 GMP?approved facilities globally.

Sector Context

• Other Indian players like Natco Pharma have also launched generic Pomalidomide in the US, intensifying competition and highlighting the broader push of Indian pharma into high-value generics.

With this launch, Aurobindo Pharma is capitalizing on its manufacturing scale, regulatory experience, and strategic filings to strengthen its foothold in the U.S. oncology segment — a space that healthcare providers and patients alike value for both innovation and affordability.